Evidence map›Paper›PMID 32669928›Full record

ArticleCurrent oncology (Toronto, Ont.)2020

PD-1 inhibition in malignant melanoma and lack of clinical response in chronic lymphocytic leukemia in the same patients: a case series.

I Landego, D Hewitt, I Hibbert, D Dhaliwal, W Pieterse, D Grenier, R Wong, J Johnston, V Banerji

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Depletion of polyfunctional CD26Experimental hematology & oncology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

I LandegoDepartment of Internal Medicine, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB.
D HewittResearch Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB.
I HibbertDepartment of Nursing, CancerCare Manitoba, Winnipeg, MB.
D DhaliwalSection of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB.
W PieterseRussell Health Centre, Community Oncology Program, Winnipeg, MB.
D GrenierSection of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB.
R WongSection of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB.
J JohnstonResearch Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB.
V BanerjiResearch Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in the Western world. Unfortunately, affected patients are often immunosuppressed and at increased risk of infection and secondary malignancy. Previous meta-analysis has found that patients with cll have a risk of melanoma that is increased by a factor of 4 compared with the general population. Recent advances in the understanding of the PD receptor pathway have led to immunotherapies that target cancer cells. The use of PD-1 inhibitors is now considered first-line treatment for

Indexed as

Aged, 80 and overFemaleHumansImmunotherapyLeukemia, Lymphocytic, Chronic, B-CellMelanomaProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 Receptorchronic lymphocytic leukemiacllImmunotherapymelanoma

Identifiers

PMID32669928
PMCPMC7339846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.